Key result
Verapamil reduced anginal frequency from 5.6 to 2.2 attacks per week and increased treadmill time compared to placebo in patients with stable exertional angina.
Why the study?
Does verapamil reduce anginal frequency and improve exercise tolerance in patients with stable exertional angina pectoris?
RCT (n=26)
Double-blind
Crossover
Does verapamil reduce anginal frequency and improve exercise tolerance in patients with stable exertional angina pectoris?
Verapamil 480 mg/day is safe and effective for reducing angina frequency and improving exercise tolerance in patients with stable exertional angina.
Answers are grounded in this paper and cite their sources.
Verapamil is effective for symptom control in stable angina; confirms its role versus placebo in this RCT.
The effects of verapamil were assessed in 26 patients with stable exertional angina pectoris in a double-blind, placebo-controlled, randomized crossover protocol using serial treadmill tests. Verapamil, 480 mg/day, reduced anginal frequency from 5.6 +/- 7.3 to 2.2 +/- 3.9 attacks per week (p less than 0.001) and nitroglycerin consumption from 3.4 +/- 4.9 to 1.2 +/- 2.5 tablets per week (p less than 0.05) compared with placebo. Treadmill time increased from 6.4 +/- 2.1 minutes during the placebo phase to 7.5 +/- 1.8 minutes during the verapamil phase (p less than 0.001). Verapamil's beneficial effect appeared to be related, in part, to a 10% reduction of the rate-pressure product at rest (p less than 0.05) and a 12% reduction during submaximal exercise (p less than 0.001). Verapamil also caused less marked ST-segment depressions at peak exercise (p less than 0.05) at a similar rate-pressure product, suggesting a favorable redistribution of coronary blood flow to the ischemic zone. Side effects from verapamil were minimal, consisting mainly of constipation (six patients). Verapamil appears to be a safe and effective drug for treating angina of effort.
No takes yet. Share an insight, caveat, or question.
Brodsky et al. (1982) conducted an RCT in Stable exertional angina pectoris (n=26). Verapamil vs. Placebo was evaluated on Anginal frequency (attacks per week) (p=<0.001). Verapamil reduced anginal frequency from 5.6 to 2.2 attacks per week and increased treadmill time compared to placebo in patients with stable exertional angina.
Synapse has enriched 10 related papers. Consider them for comparative context: